THERAPEUTIC USE OF BACTERIOPHAGES IN BACTERIAL INFECTIONS
Common use of antibiotics in the
developed world has resulted in the emergence of bacterial strains, which
are highly resistant to virtually all available antimicrobial agents (Nature 2002, 418, 469). As
a result, in most infections induced by such bacteria even intensive antibiotic
therapy is ineffective. This creates a serious therapeutic problem. Therefore,
we observe a growing interest in the use of bacteriophages in medical practice.
Since 1980 the specific bacteriophages have been used in our Laboratory
for the treatment of over 1500 patients with suppurative bacterial infections,
in which a routine antibiotic therapy failed. The results obtained so far
showed that phage therapy is safe and highly effective (the majority of patients
were cured). Phage therapy may be applied to all patients from whom isolated
bacterial strains show full sensitivity to specific phages. Of particular
importance is that two pathogens: Staphylococcus aureus and Pseudomonas
aeruginosa, which most frequently cause infections, were found to be
sensitive to specific phages in more than 80% of cases.
Our Laboratory possesses over 300
specific bacteriophage strains active against Staphylococcus aureus,
Escherichia,
Klebsiella, Enterobacter, Proteus and Pseudomonas.
We offer:
- isolation and identification of bacterial strains from the specimens of patients,
- determination of sensitivity of the isolated strains to specific bacteriophages,
- preparation of phage lysates for a therapeutic treatment.
The indications of the range of
phage therapy are as follows:
postoperative infections, mucopurulent bronchitis,
furunculosis*, otitis media, sinusitis,
abscesses cutis and decubitus ulcer, pyogenic arthritis, osteomyelitis,
suppurative infections after injuries of soft tissue, such as contusions,
burns, pyogenic infection after bone fractures, chronic infections
of the urinary tract, bacterial prostatitis.
The majority of patients were cured
Detailed information can be obtained from
Prof. A. Gorski and Dr B. Weber-Dabrowska, e-mail: agorski@ikp.pl
- [28.05.2009]
The Golden Scalpel 2008 is awarded to the team of:
Prof. Andrzej Górski, Dr Ryszard Międzybrodzki, Dr Wojciech Fortuna, Dr Sławomir Letkiewicz,
Dr Krzysztof Szufnarowski, Dr Zdzisław Pawełczyk, Dr Beata Weber-Dąbrowska, Alina Kopyt
outstanding innovators in Polish healthcare
in the first edition of "Puls Medycyny" (The Pulse of Medicine) for their participation in the project:
Phage therapy of multiresistant bacterial infections
Warsaw, 28th May, 2009
-
Badania kliniczne potwierdzają skuteczność terapii fagowej w klinice człowieka:
http://www.medicalnewstoday.com/articles/98346.php
-
Recenzja książki Bacteriophage: Genetics and Molecular Biology
-
Brytyjczycy chcą wrocławskich fagów
http://miasta.gazeta.pl/wroclaw/1,79448,4133572.html
-
Petition to the UK Prime Minister to Offer BACTERIO-PHAGE as the cure for MRSA and other hospital acquired infections
http://petitions.pm.gov.uk/MRSA-phage/
-
The Center for Phage Therapy accepts patients with drug-resistant bacterial infections.
For more information, please contact:
agorski@ikp.pl, phone (+48 71) 3709901, fax (+48 71) 3372171
Declaration of Helsinki,
http://www.wma.net/e/policy/b3.htm:
-
In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.
- [11.08.2005]
Opinia dotycząca charakteru zadania:
"Eksperymentalna terapia fagowa infekcji bakteryjnych odpornych na antybiotykoterapię
w tym MRSA"
- [15.06.2005]
Institutional Review Board (Bioethics Commission) approves experimental phage therapy in patients to be carried out at the Institute
- [22.02.2005]
Opinia dotycząca grantu 4 P05B 012 18 pt. Immunomodulacyjne oddziaływanie bakteriofagów
- [October 2003] Grant from The State Committee for Scientific Research/Ministry of Science:
Bacteriophage biotechnology in combatting drug-resistant bacterial infections and its potential application in clinical immunosuppression and oncology
- Grant from EU funds:
Operational Program - Innovative Economy, priority: The research and development of modern technologies.
Optimization of the characterization and production of therapeutic phage preparations
(consortium: Institute of Immunology and Experimental Therapy, Wroclaw; Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw; The Medical University of Warsaw).
Most representative publications
|
|
